SCHEMBL5778950

SCHEMBL5778950

CC(C)(C)OC(=O)c1cc(F)ccc1NCC(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 1/20 0.38
ADRA1B P35368 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRG2 P18507 1/20 0.38
GABRB3 P28472 1/20 0.38
GABRA5 P31644 1/20 0.38
GABRA3 P34903 1/20 0.38
GABRA2 P47869 1/20 0.38
GABRA4 P48169 1/20 0.38
GABRA6 Q16445 1/20 0.38
EGFR P00533 1/20 0.38
ALDH1A1 P00352 4/20 0.37
MAPT P10636 3/20 0.37
TDP1 Q9NUW8 1/20 0.35
KMT2A Q03164 1/20 0.35
KCNQ4 P56696 1/20 0.35
KCNQ5 Q9NR82 1/20 0.35
PKM P14618 1/20 0.35
MPO P05164 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7273570 0.85 CISD2 (0.40) ADRA1AADRA1BEGFRALDH1A1MAPT
SCHEMBL4629588 0.85 EGFR (0.49) ADRA1AADRA1BEGFRALDH1A1MAPT
SCHEMBL61257 0.84 KDM4E (0.41) ADRA1AADRA1BEGFRALDH1A1MAPT
SCHEMBL29238191 0.81 GABRA1 (0.41) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL7385926 0.80 ALDH1A1 (0.41) ADRA1AADRA1BEGFRALDH1A1MAPT
SCHEMBL219602 0.80 ADRA1A (0.55) ADRA1AADRA1BALDH1A1MAPTTDP1
SCHEMBL16168119 0.79 KEAP1 (0.49) ALDH1A1MAPTKMT2AMPO
SCHEMBL22164183 0.77 PKM (0.55) GABRA1GABRG2GABRB3GABRA5GABRA3
SCHEMBL6715512 0.76 ALDH1A1 (0.35) ADRA1AADRA1BALDH1A1PKMNR1H2
SCHEMBL19225923 0.75 CCNT1 (0.39) ALDH1A1MAPTTDP1KMT2AKCNQ4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1237874-B1 SELECTIVE NEUROKININ ANTAGONISTS SCHERING CORP (US) 2006-02-22 EP disclosed
US-6635630-B2 Respiratory system disorders; antiinflammatory agents SCHERING CORPORATION 2003-10-21 US disclosed
US-20030064980-A1 Selective neurokinin antagonists MERCK SHARP & DOHME CORP. 2003-04-03 US disclosed
EP-1237874-A2 SELECTIVE NEUROKININ ANTAGONISTS SCHERING CORPORATION (US) 2002-09-11 EP disclosed
US-20020123491-A1 SELECTIVE NEUROKININ ANTAGONISTS MERCK SHARP & DOHME CORP. 2002-09-05 US disclosed
US-6436928-B1 IN COMBINATION WITH A SELECTIVE SEROTONIN REUPTAKE INHIBITOR; SUBSTITUTED CYCLIC UREAS (IMIDAZOLIDINONES); ANTAGONISTS OF TACHYKININ RECEPTORS, IN PARTICULAR AS ANTAGONISTS OF THE NEUROPEPTIDES NEUROKININ-1 RECEPTOR (NK.SUB.1). SCHERING CORPORATION 2002-08-20 US disclosed
WO-2001044200-A2 SELECTIVE NEUROKININ ANTAGONISTS SCHERING CORPORATION (US) 2001-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020123491-A1 SELECTIVE NEUROKININ ANTAGONISTS CRHR1, CNR1, CRHR2 ADRA1A 68/4885ADRA1B 82/4885GABRA1 574/4885
US-20030064980-A1 Selective neurokinin antagonists CRHR1, CNR1, CRHR2 ADRA1A 61/4885ADRA1B 78/4885GABRA1 544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.